IMW 2021 | Risk-adapted management strategies for smoldering myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the benefits of risk-adapted management strategies for smoldering myeloma. Dr Mateos talks on the identification of low-risk smoldering myeloma, where patients can be reassessed annually, and reports that intermediate-risk patients can be assessed every four to six months without treatment. For high-risk patients, Dr Mateos highlights two studies which demonstrated a benefit of early treatment with lenalidomide. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Maria-Victoria Mateos, MD, PhD, has received honoraria from lectures and participated in boards with Janssen, BMS-Celgene, AbbVie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio and Sea-Gen.
